| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7381427 | ACLARIS | Seborrheic keratosis treatment |
Jun, 2022
(1 year, 5 months ago) | |
| US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
| US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
| US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
| US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
| US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(11 years from now) | |
Eskata is owned by Aclaris.
Eskata contains Hydrogen Peroxide.
Eskata has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Eskata are:
- US7381427
Eskata was authorised for market use on 14 December, 2017.
Eskata is available in solution;topical dosage forms.
Eskata can be used as treatment of seborrheic keratoses that are raised.
The generics of Eskata are possible to be released after 04 July, 2035.
Drugs and Companies using HYDROGEN PEROXIDE ingredient
Market Authorisation Date: 14 December, 2017
Treatment: Treatment of seborrheic keratoses that are raised
Dosage: SOLUTION;TOPICAL
More Information on Dosage
ESKATA family patents
